Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Investing.com - BTIG maintained its Buy rating and $20.00 price target on Jasper Therapeutics (NASDAQ:JSPR) following the company’s second quarter 2025 earnings report. The stock, currently trading at $2.97, has shown significant volatility with a 52-week range of $2.27-$26.05. According to InvestingPro data, analyst consensus remains moderately bullish with price targets ranging from $4 to $51.
Jasper Therapeutics announced that an update on the ongoing investigation into the 240/180mg Q8W cohorts in the BEACON study is expected later this year, according to BTIG.
The company also provided guidance that data from both new and redosed patients will be available in late 2025, while the planned Phase 2b CSU study is now scheduled to commence in mid-2026.
BTIG views Jasper’s focus on progressing briquilimab in CSU this year and concluding results from the investigation as a de-risking event and potential catalyst later this year.
The firm reiterated its Buy rating and $20 price target on Jasper Therapeutics stock based on these developments.
In other recent news, Jasper Therapeutics has faced several developments impacting its operations and stock evaluations. The company announced a significant workforce reduction, cutting approximately 50% of its employees to concentrate on its briquilimab development for chronic urticaria. This restructuring also includes the departure of Chief Medical Officer Edwin Tucker, with Daniel Adelman stepping in as Acting Chief Medical Officer. In terms of analyst ratings, JMP Securities has reiterated its Market Outperform rating and set a price target of $12.00, despite setbacks in Jasper’s CSU clinical trial program. The firm pointed to briquilimab’s promising response rates compared to competitors. However, BMO Capital downgraded Jasper Therapeutics from Outperform to Market Perform, citing concerns over potential manufacturing issues in the CSU trial. Additionally, Citizens JMP adjusted its price target for Jasper from $70.00 to $12.00, attributing the change to disappointing trial results linked to a manufacturing problem. These recent developments reflect the challenges and strategic shifts Jasper Therapeutics is navigating in its clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.